Abstract
The c-erbB3 protein is a member of the type I growth factor receptor family. It has a widespread pattern of expression in normal tissues and is overexpressed in about 20% of breast cancers. We have raised a specific monoclonal antibody, called SGP1, against the extracellular domain of c-erbB3 which recognises the native form of the protein. The monoclonal antibody was found to modestly but significantly stimulate the anchorage-independent cloning efficiency of the breast tumour cell lines BT483 and T47D, both of which express the c-erbB3 protein. No effect was observed on 293 cells lacking expression, nor did a control isotype-matched antibody promote the growth of any of the cells tested. These results suggest that the c-erbB3 protein may normally act as a growth factor receptor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rajkumar, T., Gullick, W. A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines. Br J Cancer 70, 459–465 (1994). https://doi.org/10.1038/bjc.1994.328
Issue Date:
DOI: https://doi.org/10.1038/bjc.1994.328
This article is cited by
-
HER3 in cancer: from the bench to the bedside
Journal of Experimental & Clinical Cancer Research (2022)
-
A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines
Breast Cancer Research and Treatment (2012)
-
Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?
Breast Cancer Research (2008)
-
A Novel Proliferation-Associated Variant of CFR-1 Defined by a Human Monoclonal Antibody
Laboratory Investigation (2001)